Judith Dams
Dr. rer. med.
Judith Dams
  • Research assistant
Working area

Location

W37 , 6th Floor, Room number 609
Languages
German (Mother tongue)
English

Curriculum vitae

Publications

2019

Direkte Kosten sozialer Angststörung bei Jugendlichen und Kosteneffektivität der Psychotherapie
Dams J, Kronmüller K, Leibing E, Steil R, Henningsen P, Leichsenring F, Peseschkian H, Rosner R, Salzer S, Stefini A, Vonderlin E, König H
PSYCHIAT PRAX. 2019;46(3):148-155.

Health-related quality of life measured with the EQ-5D-5L: estimation of normative index values based on a representative German population sample and value set
Grochtdreis T, Dams J, König H, Konnopka A
EUR J HEALTH ECON. 2019;20(6):933-944.

Effect of Naturally Occurring α-Synuclein-Antibodies on Toxic α-Synuclein-Fragments
Rabenstein M, Agbo D, Wolf E, Dams J, Nicolai M, Roeder A, Bacher M, Dodel R, Noelker C
NEUROSCI LETT. 2019;704:181-188.

Cognitive decline in Parkinson's disease: the impact of the motor phenotype on cognition
Wojtala J, Heber I, Neuser P, Heller J, Kalbe E, Rehberg S, Storch A, Linse K, Schneider C, Gräber S, Berg D, Dams J, Balzer-Geldsetzer M, Hilker-Roggendorf R, Oberschmidt C, Baudrexel S, Witt K, Schmidt N, Deuschl G, Mollenhauer B, Trenkwalder C, Liepelt-Scarfone I, Spottke A, Roeske S, Wüllner U, Wittchen H, Riedel O, Dodel R, Schulz J, Reetz K
J NEUROL NEUROSUR PS. 2019;90(2):171-179.

2018

Excess costs of alcohol-dependent patients in German psychiatric care compared with matched non-alcohol-dependent individuals from the general Population: a secondary analysis of two datasets
Dams J, Buchholz A, Kraus L, Reimer J, Scherbaum N, Konnopka A, König H
BMJ OPEN. 2018;8:e020563.

Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review
Grochtdreis T, König H, Dobruschkin A, von Amsberg G, Dams J
PLOS ONE. 2018;13(12):e0208063.

Cost-utility of collaborative nurse-led self-management support for primary care patients with anxiety, depressive or somatic symptoms: A cluster-randomized controlled trial (the SMADS trial)
Grochtdreis T, Zimmermann T, Puschmann E, Porzelt S, Dams J, Scherer M, König H
INT J NURS STUD. 2018;80:67-75.

Comparison of a group-delivered and individually delivered lifestyle-integrated functional exercise (LiFE) program in older persons: a randomized noninferiority trial
Jansen C, Nerz C, Kramer F, Labudek S, Klenk J, Dams J, König H, Clemson L, Becker C, Schwenk M
BMC GERIATR. 2018;18(1):267.

Costs of Illness in Chronic Inflammatory Demyelinating Polyneuropathy in Germany
Mengel D, Fraune L, Sommer N, Stettner M, Reese J, Dams J, Glynn R, Balzer-Geldsetzer M, Dodel R, Tackenberg B
MUSCLE NERVE. 2018;58(5):681-687.

2017

Excess costs of social anxiety disorder in Germany
Dams J, König H, Bleibler F, Hoyer J, Wiltink J, Beutel M, Salzer S, Herpertz S, Willutzki U, Strauß B, Leibing E, Leichsenring F, Konnopka A
J AFFECT DISORDERS. 2017;213:23-29.

19 Kosten-Nutzen-Analysen zur tiefen Hirnstimulation bei Patienten mit idiopathischem Parkinson-Syndrom
Dodel R, Dams J, Reese J
2017. Tiefe Hirnstimulation. 1. ed. Berlin: De Gryter, 181-192.

2016

Cost-effectiveness of neurostimulation in Parkinson's disease with early motor complications
Dams J, Balzer-Geldsetzer M, Siebert U, Deuschl G, Schuepbach W, Krack P, Timmermann L, Schnitzler A, Reese J, Dodel R
MOVEMENT DISORD. 2016;31(8):1183-91.

An economic evaluation of deep brain stimulation for patients with Parkinson's disease
Dams J, Dodel R
MOVEMENT DISORD. 2016;31(8):1122-1124.

Verbal memory declines more in female patients with Parkinson's disease: the importance of gender-corrected normative data
Fengler S, Roeske S, Heber I, Reetz K, Schulz J, Riedel O, Wittchen H, Storch A, Linse K, Baudrexel S, Hilker R, Mollenhauer B, Witt K, Schmidt N, Balzer-Geldsetzer M, Dams J, Dodel R, Gräber S, Pilotto A, Petrelli A, Fünkele S, Kassubek J, Kalbe E
PSYCHOL MED. 2016;46(11):2275-2286.

Health-Related Quality of Life in Patients with Alzheimer's Disease in Different German Health Care Settings
Heßmann P, Seeberg G, Reese J, Dams J, Baum E, Müller M, Dodel R, Balzer-Geldsetzer M
J ALZHEIMERS DIS. 2016;51(2):545-561.

Subtypes of mild cognitive impairment in patients with Parkinson's disease: evidence from the LANDSCAPE study
Kalbe E, Rehberg S, Heber I, Kronenbuerger M, Schulz J, Storch A, Linse K, Schneider C, Gräber S, Liepelt-Scarfone I, Berg D, Dams J, Balzer-Geldsetzer M, Hilker R, Oberschmidt C, Witt K, Schmidt N, Mollenhauer B, Trenkwalder C, Spottke A, Roeske S, Wittchen H, Riedel O, Dodel R
J NEUROL NEUROSUR PS. 2016;87(10):1099-1105.

Apolipoprotein E ε4 does not affect cognitive performance in patients with Parkinson's disease
Mengel D, Dams J, Ziemek J, Becker J, Balzer-Geldsetzer M, Hilker R, Baudrexel S, Kalbe E, Schmidt N, Witt K, Liepelt-Scarfone I, Gräber S, Petrelli A, Neuser P, Schulte C, Linse K, Storch A, Wittchen H, Riedel O, Mollenhauer B, Ebentheuer J, Trenkwalder C, Klockgether T, Spottke A, Wüllner U, Schulz J, Reetz K, Heber I, Ramirez A, Dodel R
PARKINSONISM RELAT D. 2016;29:112-6.

2013

Mapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson's disease
Dams J, Klotsche J, Bornschein B, Reese J, Balzer-Geldsetzer M, Winter Y, Schrag A, Siderowf A, Oertel W, Deuschl G, Siebert U, Dodel R
HEALTH QUAL LIFE OUT. 2013;11:35.

Cost-effectiveness of deep brain stimulation in patients with Parkinson's disease
Dams J, Siebert U, Bornschein B, Volkmann J, Deuschl G, Oertel W, Dodel R, Reese J
MOVEMENT DISORD. 2013;28(6):763-771.

2012

Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses
Pouryamout L, Dams J, Wasem J, Dodel R, Neumann A
DRUGS. 2012;72(6):789-802.

Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease
Reese J, Dams J, Winter Y, Balzer-Geldsetzer M, Oertel W, Dodel R
EXPERT OPIN PHARMACO. 2012;13(7):939-958.

2011

Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review
Dams J, Bornschein B, Reese J, Conrads-Frank A, Oertel W, Siebert U, Dodel R
PHARMACOECONOMICS. 2011;29(12):1025-1049.

2010

Health-related quality of life in patients with subarachnoid haemorrhage
Meyer B, Ringel F, Winter Y, Spottke A, Gharevi N, Dams J, Balzer-Geldsetzer M, Mueller I, Klockgether T, Schramm J, Urbach H, Dodel R
CEREBROVASC DIS. 2010;30(4):423-431.

Letzte Aktualisierung aus dem FIS: 15.10.2019 - 05:16 Uhr